Dermata Therapeutics Net Income Over Time
| DRMA Stock | USD 1.83 0.06 3.39% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Dermata Therapeutics Performance and Dermata Therapeutics Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dermata Therapeutics. Projected growth potential of Dermata fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Dermata Therapeutics assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Dermata Therapeutics's market price often diverges from its book value, the accounting figure shown on Dermata's balance sheet. Smart investors calculate Dermata Therapeutics' intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Since Dermata Therapeutics' trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Dermata Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Dermata Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Dermata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Dermata Therapeutics and related stocks such as Avenue Therapeutics, Windtree Therapeutics, and Carisma Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WINT | (2.8 M) | (21 M) | (37.3 M) | (45.2 M) | (44.1 M) | (55.2 M) | (39.5 M) | (18.4 M) | (20.5 M) | (27.5 M) | (30.3 M) | (67.6 M) | (39.2 M) | (20.3 M) | (5.5 M) | (4.9 M) | (5.2 M) |
| CARM | (13 M) | (13 M) | (19.8 M) | (19.4 M) | (34.5 M) | (33.5 M) | 1.9 M | (29 M) | (33.7 M) | (107.5 M) | (28.3 M) | (336 K) | (61.2 M) | (86.9 M) | (60.5 M) | (54.4 M) | (57.2 M) |
| PBM | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8.2 M | 8 M | (51.2 M) | 1 M | 910.6 K | 956.1 K |
| LIPO | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.8 K) | (61.7 K) | (1.9 M) | (2.6 M) | (4.6 M) | (5 M) | (4.5 M) | (4.3 M) |
| VRAX | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (801.1 K) | (651 K) | (1.7 M) | (5.5 M) | (6.7 M) | (6.1 M) | (5.5 M) | (5.7 M) |
| ELAB | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (222.9 K) | (784.7 K) | (1.8 M) | (4.3 M) | (6.2 M) | (5.6 M) | (5.3 M) |
| GTBP | 150 K | (3.7 M) | (5.2 M) | (501 K) | (23.5 M) | (21.5 M) | 9.8 M | (144.2 M) | (259.2 M) | (38.6 M) | (28.3 M) | (58 M) | (20.9 M) | (7.6 M) | (13.2 M) | (11.8 M) | (12.4 M) |
| REVB | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.2 M | 8.8 M | 16.3 M | 27.6 M | (3.6 K) | (136.4 K) | (12 M) | (10.8 M) | (120.3 K) | (15 M) | (13.5 M) | (12.9 M) |
| ARTL | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.3 K) | (15.2 K) | (29.7 K) | (234.9 K) | (2.3 M) | (2.2 M) | (4.7 M) | (7.4 M) | (10.1 M) | (9.3 M) | (9.8 M) | (8.8 M) | (8.4 M) |
Dermata Therapeutics and related stocks such as Avenue Therapeutics, Windtree Therapeutics, and Carisma Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Dermata Therapeutics financial statement analysis. It represents the amount of money remaining after all of Dermata Therapeutics operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Dermata Therapeutics | DRMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 3525 Del Mar |
| Exchange | NASDAQ Exchange |
USD 1.83
Check out Dermata Therapeutics Performance and Dermata Therapeutics Correlation. For information on how to trade Dermata Stock refer to our How to Trade Dermata Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Dermata Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.